Immunological Reaction of the Recipient After Cold-stored Saphenous Venous Allograft (Bioprotec)
Centre Hospitalier Universitaire de Nīmes
50 participants
Jun 8, 2022
OBSERVATIONAL
Conditions
Summary
The study investigators propose to perform a blood test before and after allograft placement in all patients receiving a cold-stored venous allografts at the University Hospital of Nîmes to study the occurrence of FVFA-related ASD in these patients. The aim of this work is to characterize a possible immune reaction generated by the implantation of venous allografts prepared according to the BIOPROTEC method. In case of a proven immune reaction, the study will allow a modification of our current attitude and to exclude patients potentially eligible for renal transplantation at the time of venous allograft placement, or to perform in these patients an allo-compatibility test with the venous allograft preoperatively and thus protect these patients from an increased risk of subsequent organ transplant rejection.
Eligibility
Inclusion Criteria2
- The patient must be a member or beneficiary of a health insurance plan
- Patients receiving a scheduled venous allograft within the CHU of Nîmes for an arterial bypass in the lower limb or an arteriovenous bypass in the upper limb within the framework of the creation of arteriovenous fistulas in dialysis patients, in the absence of available autologous venous material.
Exclusion Criteria7
- The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
- The subject has already been included in the study
- The subject refuses to participate
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient previously having received a venous allograft or organ transplant
- Pregnant, parturient or breastfeeding patients
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05096351